Increase in hepatic carnitine acetyltransferase activity associated with peroxisomal (microbody) proliferation induced by the hypolipidemic drugs clofibrate, nafenopin, and methyl clofenapate.
D000123:Acetyltransferases / Q000378:metabolism*; D000818:Animals; D001713:Biphenyl Compounds / Q000494:pharmacology*; D002087:Butyrates / Q000494:pharmacology*; D002331:Carnitine; D002374:Catalase / Q000097:blood; D002994:Clofibrate / Q000494:pharmacology*; D004987:Ethers / Q000494:pharmacology; D005260:Female; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008099:Liver / Q000201:enzymology* / Q000648:ultrastructure; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008830:Microbodies / Q000201:enzymology*; D008854:Microscopy, Electron; D009255:Nafenopin / Q000494:pharmacology*; D009929:Organ Size; D009940:Organoids / Q000201:enzymology*; D010477:Perfusion; D011422:Propionates / Q000494:pharmacology*; D051381:Rats; D012737:Sex Factors; D013268:Stimulation, Chemical
D001713:Biphenyl Compounds; D002087:Butyrates; D004987:Ethers; D000960:Hypolipidemic Agents; D011422:Propionates; D009255:Nafenopin; D002374:Catalase; D000123:Acetyltransferases; D002994:Clofibrate; D002331:Carnitine